Czechia· CZ-0285989
DESFERAL
A deferoxamine product containing deferoxamine mesilate + water for injections + nitrogen, registered in Czechia by MITEM PHARMA SAS, Massy. The same ATC class is registered in 16 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Deferoxamine is registered in 16 of 19 countries.
Countries holding a registration under ATC V03AC01 (deferoxamine), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 10 of them publish a price we can compare per daily dose
Deferoxamine · ATC V03AC01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of deferoxamine costs, country by country.
Normalised to the WHO defined daily dose (2.8 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Deferoxamine · price per daily dose (2.8 g)
USD · FX 28 Sept 2026
- CH Switzerland$48.38
- FR France$33.66
The record
At a glance
SÚKL (Czech Republic)- Active substance
- DEFEROXAMINE MESILATE + WATER FOR INJECTIONS + NITROGEN
- Manufacturer
- MITEM PHARMA SAS, Massy
- Country
- Czechia (CZ)
- ATC code
- V03AC01
- ATC class
- Deferoxamine
- Defined daily dose
- 2.8 g, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
49 interactions on record for deferoxamine.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Deferoxamine · interactions on record
49 records
- 9 severe
- 5 moderate
- 35 info
Most severe, free to view
- CidofovirJ05AB12severe
- VigabatrinN03AG04severe
- InotersenN07XX15severe
- IopamidolV08AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under V03AC01
Deferoxamine, as other registers publish it.
- ItalyDEFEROXAMINA NORIDEMNORIDEM ENTERPRISES LTD
- ItalyDEFEROXAMINA*1 flaconcino iniett 2 gNORIDEM ENTERPRISES LTD
- United StatesDeferoxamineFresenius Kabi USA, LLC
- United StatesDeferoxamineFresenius Kabi USA, LLC
- United StatesDeferoxamineFresenius Kabi USA, LLC
- United StatesDeferoxamineFresenius Kabi USA, LLC
- United StatesDeferoxamine mesylateApotex Corp.
- United StatesDeferoxamine mesylateGland Pharma Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f6e8bd5b-1076-4c2f-936f-60103e2dc445 GET /v1/drugs/f6e8bd5b-1076-4c2f-936f-60103e2dc445?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ PLV SOL",
"source": "sukl",
"strength": "500MG",
"pack_size": "50",
"substance": "DEFEROXAMINE MESILATE + WATER FOR INJECTIONS + NITROGEN",
"cz_kod_sukl": "0285989",
"product_type": "CH",
"substance_codes": "2148,2044,3068",
"registration_state": "R",
"registration_number": "19/050/70-C"
}See everything about deferoxamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.